Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04781127 · ClinicalTrials.gov registry record · Phase 1
Home-administered tDCS for Treatment of Depression
A Phase 1 study of Treatment-Resistant Depression and Unipolar Depression, sponsored by Soterix Medical.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04781127: Completed Phase 1 study of Treatment-Resistant Depression and Unipolar Depression, sponsored by Soterix Medical.
NCT04781127 is a Phase 1 study of Treatment-Resistant Depression and Unipolar Depression that has completed, run by Soterix Medical. The registered enrollment target is 50 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04781127, a Phase 1 study of Treatment-Resistant Depression and Unipolar Depression, has completed, sponsored by Soterix Medical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT. 32 tDCS sessions of 30 minutes each will be delivered over 10 weeks.
Primary Outcome
Mood will be assessed with the Montgomery Asberg Depression Rating Scale (MADRS). Patients who meet criteria for clinical response (\>=50% improvement in MADRS) may continue with maintenance treatments of once a week for 2 months and once every 2 weeks for the remaining 3 months.
Conditions Studied
Interventions
- DEVICE Soterix Medical mini-CT tDCS stimulator
Study Locations (1)
New York
- New York University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-02-10 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 1 |
What the finished NCT04781127 record still lists
NCT04781127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower).
The record links to 2 conditions, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Soterix Medical mini-CT tDCS stimulator is the first listed.
NCT04781127 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04781127 about?
NCT04781127 is a clinical study titled "Home-administered tDCS for Treatment of Depression". This study will determine the safety and efficacy of home administered tDCS in adults with unipolar depression. The device used to administer tDCS will be the Soterix Medical 1X1 mini-CT. 32 tDCS sessions of 30 minutes each will be delivered over 10 weeks.
What is the current status of trial NCT04781127?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-02-10. Estimated completion is 2022-08-10.
What conditions does trial NCT04781127 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression, Unipolar Depression.
What interventions are being tested in trial NCT04781127?
The interventions under investigation include: Soterix Medical mini-CT tDCS stimulator (DEVICE).
Who is sponsoring clinical trial NCT04781127?
This trial is sponsored by Soterix Medical, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04781127 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04781127's enrollment target sits among peer trials
50 28th of 54 higher than 26 of 54 other Treatment-Resistant Depression trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Treatment-Resistant Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DBS for Depression
RECRUITING · Phase 1
-
Slow Wave Induction by Propofol to Eliminate Depression (SWIPED) I
ACTIVE NOT RECRUITING · Phase 1
-
Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression
COMPLETED · Phase 1
-
Multiple Ascending Dose Phase 1 Study of ALA-3000
COMPLETED · Phase 1
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI